MSI TESTING
EXPLAINED
MSI-H is the molecular feature that produces the most dramatic treatment consequence per positive result. Any cancer type. Any organ. If MSI-H, pembrolizumab is approved -- the first-ever tumour-agnostic drug approval in oncology history.
MSI-H Clinical Significance at a Glance
- 2017Year of first tumour-agnostic cancer drug approval (pembrolizumab for MSI-H)
- 5%Approximate prevalence of MSI-H in metastatic colorectal cancer
- 20-30%Prevalence of MSI-H/dMMR in endometrial cancer
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About MSI Status and Immunotherapy Eligibility?
CancerFax reviews your MSI, TMB, and PD-L1 results together to assess the complete immunotherapy eligibility picture for your specific cancer.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.